CDK7 Inhibitor Could Prevent Chemotherapy-Related Heart Damage
Blocking CDK7 prevents heart damage from cancer chemotherapy medication doxorubicin.
New research describes a strategy to counter chemotherapy-induced heart damage.
Image credit: Khwanchai Phanthongs
- Blocking CDK7 could prevent heart damage associated with doxorubicin chemotherapy treatment.
- Inhibiting CDK7 could enhance cancer-killing capability of doxorubicin.
- Study findings suggest that combining doxorubicin and a CDK7 inhibitor (THZ1) could help prevent heart damage and increase chemotherapy effectiveness.
- THZ1 (CDK7 inhibitor) increased heart function while inhibiting tumor growth in animal model.
- Further research is needed to test the effect of THZ1 on heart damage and cancer growth in younger mice and longer-term follow-up.
Source: Washington State University